Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms

2007 ◽  
Vol 120 (1) ◽  
pp. 72-82.e3 ◽  
Author(s):  
Russell D. Hull ◽  
Graham F. Pineo ◽  
Rollin F. Brant ◽  
Andrew F. Mah ◽  
Natasha Burke ◽  
...  
1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.


2005 ◽  
Vol 11 (3) ◽  
pp. 157-162 ◽  
Author(s):  
EMMANUEL J. FAVALORO ◽  
ROSLYN BONAR ◽  
MARGARET ABOUD ◽  
JOYCE LOW ◽  
JOHN SIOUFI ◽  
...  

2014 ◽  
Vol 111 (03) ◽  
pp. 559-561 ◽  
Author(s):  
Esteban Gándara ◽  
Marc Carrier ◽  
Marc Rodger

Note: The contact information for Drs. Gandara and Carrier is the same as for Dr. Rodger. Their e-mail addresses are [email protected] and [email protected], respectively.


1988 ◽  
Vol 18 (3) ◽  
pp. 78-81
Author(s):  
J. Harenberg ◽  
G. Leber ◽  
R. Raedsch ◽  
R. Zimmermann ◽  
F. Schwarz ◽  
...  

1998 ◽  
Vol 79 (04) ◽  
pp. 756-761 ◽  
Author(s):  
Paul Monagle ◽  
Maureen Andrew ◽  
Jacqueline Halton ◽  
Richard Marlar ◽  
Lawrence Jardine ◽  
...  

SummaryWe present a kindred with a new mutation of the protein C gene, in which the proband had an unusual clinical presentation. The relationship between warfarin induced skin necrosis and level of anticoagulation was investigated. The pharmacokinetics of protein C concentrate was assessed to determine frequency of replacement therapy. The clinical and biochemical efficacy of therapy with low molecular weight heparin (LMWH) was assessed. The effect of long-term LMWH on bone density in the growing child was monitored using whole body densitometry.Warfarin therapy required an INR of greater than 3.5 to avoid skin necrosis. If protein C replacement was to be used, doses of 100 U/kg/day would have been required to maintain protein C levels consistently at or above 0.20 U/ml. While receiving prophylactic therapy with LMWH for almost 3 years, there were no episodes of recurrent thrombosis, no skin necrosis and no bleeding. Biochemical markers of in vivo thrombin generation were suppressed and within the normal range. Bone density continued to increase at the normal rate throughout the treatment period.LMWH is an effective form of long-term therapy for homozygous protein C deficient patients with measurable protein C levels.


Sign in / Sign up

Export Citation Format

Share Document